Postmenopausal women have an increased maximal platelet reactivity compared to men despite dual antiplatelet therapy

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 8, 2012, Pages 723-728

  Bobbert, Peter ^a   Stellbaum, Caroline ^a   Steffens, Daniel ^a   Schütte, Claudia ^a   Bobbert, Thomas ^a   Schultheiss, Heinz Peter ^a   Rauch, Ursula ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

acetylsalicylic acid; clopidogrel; platelets; sex

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CELL STIMULATION; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SEX DIFFERENCE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; TREATMENT DURATION;

ADENOSINE DIPHOSPHATE; AGED; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POSTMENOPAUSE; PROSPECTIVE STUDIES; SEX FACTORS; TICLOPIDINE;

EID: 84870182711     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835824b3     Document Type: Article

References (36)

1. Chesebro JH, Rauch U, Fuster V, Badimon JJ. Pathogenesis of thrombosis in coronary artery disease. Haemostasis 1997; 27 (Suppl 1):12-18. (Pubitemid 27521231)
2. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527-533. (Pubitemid 32772726)
3. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001; 134:224-238. (Pubitemid 32113325)
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502. (Pubitemid 32758501)
5. Sharma RK, Reddy HK, Singh VN, Sharma R, Voelker DJ, Bhatt G. Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag 2009; 5:965-972.
6. Stellbaum C, Willich T, Boltzen U, Ayral Y, Szotowski B, Piorkowski M, et al. Clopidogrel-mediated reduction of circulating tissue factor in patients with stable coronary artery disease. Eur J Haematol 2007; 78:347-352. (Pubitemid 46365084)
7. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109:3171-3175.
8. Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 2010; 126:e318-e322.
9. Rauch U, Ziegler D, Piolot R, Schwippert B, Benthake H, Schultheiss HP, Tschoepe D. Platelet activation in diabetic cardiovascular autonomic neuropathy. Diabet Med 1999; 16:848-852. (Pubitemid 29498224)
10. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-375.
11. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360:354-362.
12. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975; 253:355-357.
13. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:1293-1304.
14. Ivandic BT, Schlick P, Staritz P, Kurz K, Katus HA, Giannitsis E. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. Clin Chem 2006; 52:383-388.
15. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53:849-856.
16. Siller-Matula JM, Christ G, Lang IM, Le-Karth G, Huber K, Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010; 8:351-359.
17. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events poststenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46:1820-1826. (Pubitemid 41579802)
18. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009; 30:426-435.
19. Piorkowski M, Weikert U, Schwimmbeck PL, Martus P, Schultheiss HP, Rauch U. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost 2004; 92:614-620. (Pubitemid 39248019)
20. Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higherdose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007; 49:1035-1042. (Pubitemid 46349499)
21. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006; 295:1420-1427.
22. Akarasereenont P, Tripatara P, Chotewuttakorn S, Palo T, Thaworn A. The effects of estrone, estradiol and estriol on platelet aggregation induced by adrenaline and adenosine diphosphate. Platelets 2006; 17:441-447. (Pubitemid 44665566)
23. Moro L, Reineri S, Piranda D, Pietrapiana D, Lova P, Bertoni A, et al. Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. Blood 2005; 105:115-121. (Pubitemid 40053072)
24. De Luca G, Gibson CM, Gyongyosi M, Zeymer U, Dudek D, Arntz HR, et al. Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis 2010; 30:342-346.
25. Lawesson SS, Stenestrand U, Lagerqvist B, Wallentin L, Swahn E. Gender perspective on risk factors, coronary lesions and long-term outcome in young patients with ST-elevation myocardial infarction. Heart 2010; 96:453-459.
26. Mikkola T, Turunen P, Avela K, Orpana A, Viinikka L, Ylikorkala O. 17 betaestradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J Clin Endocrinol Metab 1995; 80:1832-1836.
27. Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 1995; 91:2742-2747.
28. Pinto S, Coppo M, Paniccia R, Prisco D, Gori AM, Attanasio M, Abbate R. Sex related differences in platelet TxA2 generation. Prostaglandins Leukot Essent Fatty Acids 1990; 40:217-221. (Pubitemid 20223369)
29. Kelton JG, Powers P, Julian J, Boland V, Carter CJ, Gent M, Hirsh J. Sexrelated differences in platelet aggregation: influence of the hematocrit. Blood 1980; 56:38-41. (Pubitemid 10086955)
30. Bochsen L, Johansson PI, Kristensen AT, Daugaard G, Ostrowski SR. The influence of platelets, plasma and red blood cells on functional haemostatic assays. Blood Coagul Fibrinolysis 2011; 22:167-175.
31. Hobson AR, Qureshi Z, Banks P, Curzen N. Gender and responses to aspirin and clopidogrel: insights using short thrombelastography. Cardiovasc Ther 2009; 27:246-252.
32. Ivandic BT, Giannitsis E, Schlick P, Staritz P, Katus HA, Hohlfeld T. Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem 2007; 53:614-619. (Pubitemid 46580230)
33. Zwierzina WD, Kunz F, Kogelnig R, Herold M. Sex-related differences in platelet aggregation in native whole blood. Thromb Res 1987; 48:161-171. (Pubitemid 18050943)
34. Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost 2010; 104:471-484.
35. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost 1997; 77:748-754. (Pubitemid 27182975)
36. Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont P, Bray PF. Platelet hyperreactivity in women from families with premature atherosclerosis. J Am Med Womens Assoc 2003; 58:272-277.